Effects of Shenqi fuzheng injection for treatment of patients with lung cancer and obstructive pulmonary infection and its effects on serum cell cytokine

doi:10.3877/cma.j.issn.1674-1358.2019.01.012

Abstract

Abstract:

Objective

To investigate the effect of Shenqi Fuzheng injection on serum cytokines in patients with lung cancer complicated with obstructive pulmonary infection.

Methods

Total of 104 patients with lung cancer complicated with obstructive pulmonary infection treated in Qiaotou Hospital of Dongguan City from February 2016 to February 2018 were collected, and were randomly divided into study group (52 cases) and control group (52 cases). The patients in control group were treated with routine treatment for lung cancer and obstructive pulmonary infection, while patients in study group were treated with Fuzheng injection for adjuvant treatment on the basis of routine treatment. Clinical efficacy and related clinical indexes such as the levels of procalcitonin (PCT), hypersensitive C-reactive protein (hs-CRP), matrix metalloproteinase-9 (MMP-9), interleukin-6 (IL-8) and interleukin-8 (IL-8) in serum of patients in both groups before and after treatment, and adverse reaction rate were compared, respectively.

Results

The total effective rate was 96.15% (50/52) of patients in study group, which was significantly higher than that of the control group [82.69% (43/52)], with significant differences (χ² = 4.981, P = 0.026). The recovery period of body temperature and white blood cell count, the hospital stay period of patients in study group were shorter than those of the control group (t = 4.107, 2.359, 6.017; all P < 0.05). The levels of serum PCT, hs-CRP, MMP-9, IL-6 and IL-8 of patients in study group were significantly lower than those of control group after treatment, with significant differences (t = 22.324, 3.531, 10.156, 20.866, 21.583; all P < 0.05). The incidence of adverse reactions of patients in study group was significantly lower than that of the control group, with significant differences (χ² = 4.727, P = 0.030).

Conclusions

Shenqi fuzheng injection is effective in the treatment of lung cancer complicated with obstructive pulmonary infection. It is beneficial to the rehabilitation of patients with lung cancer and could effectively reduce the level of serum cytokines with good security.

Key words: Lung cancer, Obstructive pulmonary infection, Shenqi fuzheng injection, Hypocalcitonin, Matrix metalloproteinase-9

Rongchang Lai, Songliu Mo, Fengxing Mo. Effects of Shenqi fuzheng injection for treatment of patients with lung cancer and obstructive pulmonary infection and its effects on serum cell cytokine[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(01): 60-64.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2019.01.012

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2019/V13/I01/60

Figures/Tables 5

References 25

[1]	张英, 王学谦, 刘浩, 等. 参一胶囊联合化疗改善晚期非小细胞肺癌患者预后的多中心大样本随机临床研究[J]. 中华肿瘤杂志,2018,40(4):295-299.
[2]	童艳祝, 刘宇, 姜秋. 影像学检查在肺炎性假瘤发病机理,临床特点及肺部感染分析中的应用[J]. 临床医学研究与实践,2017,2(6):45-46.
[3]	乔力松, 许小毛, 杨鹤, 等. 肺癌,消化及泌尿系恶性肿瘤合并静脉血栓栓塞症的临床特点及预后比较[J]. 中华医学杂志,2018,98(18):1403-1407.
[4]	王莎莎, 张文丰, 张登峰, 等. 红光照射对维持性血液透析患者血磷影响的研究[J]. 国际生物医学工程杂志,2017,40(3):201-204.
[5]	夏俊, 于在诚, 聂弘, 等. 合并慢性阻塞性肺疾病对老年肺癌患者术后并发症及预后的影响[J]. 中国老年学杂志,2015,38(11):3066-3067.
[6]	杨波, 姜宏宁, 余敏, 等. 老年临终期肿瘤患者合并肺部感染的危险因素分析[J]. 中华老年多器官疾病杂志,2014,33(5):364-367.
[7]	李赞, 王荣华. 肺癌术前新辅助化疗是否增加肺部感染的对比研究[J]. 西南国防医药,2017,27(2):159-161.
[8]	王红梅, 王磊. 老年肺癌伴肺部感染临床分析[J]. 中国医刊,2017,52(9):53-55.
[9]	王琳, 温子禄, 陈辉, 等. HIV感染合并非小细胞肺癌手术治疗患者的临床疗效和预后转归的观察[J]. 临床肺科杂志,2018,23(2):195-199.
[10]	宁雅婵, 高喜翔, 黄莹, 等. 降钙素原与白细胞介素6在老年肺癌患者术后肺部感染中的临床意义[J]. 肿瘤研究与临床,2017,29(5):334-337.
[11]	张淼, 刘文静, 郝璐, 等. 晚期肺癌合并慢阻肺化疗后肺部感染的病原谱及耐药性分析[J]. 临床肺科杂志,2015,20(9):1611-1614.
[12]	杨波, 姜宏宁, 余敏, 等. 老年临终期肿瘤患者合并肺部感染的危险因素分析[J]. 中华老年多器官疾病杂志,2014,13(5):364-367.
[13]	水会锋. 参芪扶正注射液在老年小细胞肺癌患者化疗中的临床价值[J]. 中国老年学杂志,2017,37(13):3238-3240.
[14]	李灵霞. 参芪扶正注射液结合化疗在老年非小细胞肺癌患者治疗中的应用[J]. 临床研究,2017,25(08):149-149.
[15]	芦秀琼, 杜英堂, 邢鑫, 等. 参芪扶正注射液辅助治疗肺癌合并阻塞性肺部感染的疗效及对血清PCT与hs-CRP及MMP-9的影响[J]. 中华医院感染学杂志,2018,28(3):367-370.
[16]	林琪, 陈明聪, 陈德连, 等. 参芪扶正注射液联合化疗对老年非小细胞肺癌患者免疫功能及肿瘤标志物的影响[J]. 中国生化药物杂志,2017,22(4):69-71.
[17]	Ding G, Liu Y, Liang C, et al. Efficacy of radiotherapy on intermediate and advanced lung cancer and its effect on dynamic changes of serum vascular endothelial growth factor and matrix metalloproteinase-9[J]. Oncol Lett,2018,16(1):219-224.
[18]	He W, Zhang H, Wang Y, et al. CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9[J]. BMC Cancer,2018,18(1):400-402.
[19]	Akamine T, Takada K, Toyokawa G, et al. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers[J]. Surg Oncol,2018,27(1):88-94.
[20]	Nagata M, Ito H, Matsuzaki T, et al. Body mass index, C-reactive protein and survival in smokers undergoing lobectomy for lung cancer[J]. Eur J Cardiothorac Surg,2017,51(6):1164-1170.
[21]	Zuo J, Wen M, Li S, et al. Overexpression of CXCR4 promotes invasion and migration of non-small cell lung cancer via EGFR and MMP-9[J]. Oncol Lett,2017,14(6):7513-7521.
[22]	Shao N, Cai Q. High pretreatment serum C-reactive protein level predicts a poor prognosis for combined small-cell lung cancer[J]. Tumour Biol,2015,36(11):8465-8470.
[23]	Chen QJ, Shi Y, Shi JF, et al. Liver X receptors agonist T0901317 downregulates matrix metalloproteinase-9 expression in non-small-cell lung cancer by repressing nuclear factor-κB[J]. Anticancer Drugs,2017,28(9):952-958.
[24]	Lake J, Mak V, Møller H, et al. Variation, precision and validity of 1-year survival estimates for lung, breast, colon and prostate cancer in South East England primary care trusts[J]. Public Health,2012,126(1):57-63.
[25]	Koh YW, Lee HW. Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy[J]. Medicine (Baltimore),2017,96(19):6848-6849.

组别	例数	性别（男/女）	年龄（±s）	病程（±s）	肿瘤类型[例（%）]
组别	例数	性别（男/女）	年龄（±s）	病程（±s）	鳞状细胞癌	腺癌	小细胞癌
研究组	52	29/23	56.32 ± 6.32	1.72 ± 0.35	27（51.92）	17（32.69）	8（15.38）
对照组	52	28/24	56.40 ± 6.37	1.75 ± 0.36	26（50.00）	19（36.54）	7（13.46）
统计量	?	0.039	t = 0.064	t = 0.431	χ²= 1.247
P值	?	0.844	0.949	0.668	0.102

组别	例数	性别（男/女）	年龄（±s）	病程（±s）	肿瘤类型[例（%）]
组别	例数	性别（男/女）	年龄（±s）	病程（±s）	鳞状细胞癌	腺癌	小细胞癌
研究组	52	29/23	56.32 ± 6.32	1.72 ± 0.35	27（51.92）	17（32.69）	8（15.38）
对照组	52	28/24	56.40 ± 6.37	1.75 ± 0.36	26（50.00）	19（36.54）	7（13.46）
统计量	?	0.039	t = 0.064	t = 0.431	χ²= 1.247
P值	?	0.844	0.949	0.668	0.102

组别	例数	显效	有效	无效	总有效率
研究组	52	28（53.85）	22（42.31）	2（3.85）	50（96.15）
对照组	52	24（46.15）	19（36.54）	9（17.31）	43（82.69）
χ²值	?	0.615	0.362	4.981	4.981
P值	?	0.433	0.547	0.026	0.026

组别	例数	显效	有效	无效	总有效率
研究组	52	28（53.85）	22（42.31）	2（3.85）	50（96.15）
对照组	52	24（46.15）	19（36.54）	9（17.31）	43（82.69）
χ²值	?	0.615	0.362	4.981	4.981
P值	?	0.433	0.547	0.026	0.026

组别	例数	体温恢复时间	白细胞计数恢复时间	住院天数
观察组	52	3.69 ± 1.57	7.12 ± 3.01	14.83 ± 3.82
对照组	52	5.41 ± 2.58	8.55 ± 3.17	19.80 ± 4.57
t值	?	4.107	2.359	6.017
P值	?	<0.001	0.020	<0.001

Please choose a citation manager

Content to export